About Index Trending news
Analyze
Pricing
Trevi Therapeutics

Trevi Therapeutics

Work at Trevi Therapeutics? Add yourself to this profile

Trevi Therapeutics

Trevi Therapeutics is a drug development company founded in 2011 focused on developing Nalbuphine ER for the severe chronic itching condition known as pruritus.

Elsewhere

Contributors to this profile

Alexa global traffic share

Twitter followers

Latest funding Show all
Venture capital (Series C)
$50,500,000
Omega Funds, TPG Biotechnology Partners, Aperture Venture Partners, +2
Debt financing
$15,000,000
Square 1 Bank, Solar capital
Employees

Team size

2
Locations
HQ
Headquarters
$50,500,000 Venture capital (Series C)
PE Hub

NEA leads $50.5 mln Series C round in Trevi Therapeutics

Health Funding Science
$15,000,000 Debt financing
abladvisor

Solar Capital, Square 1 Bank Provide $15MM Facility to Trevi Therapeutics - News | ABL Advisor